PROCEPT BioRobotics (PRCT) to Release Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) is anticipated to release its earnings data after the market closes on Tuesday, February 25th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.34) per share and revenue of $66.79 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock opened at $67.61 on Tuesday. The firm has a fifty day moving average of $78.51 and a two-hundred day moving average of $79.80. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of -34.67 and a beta of 1.03. PROCEPT BioRobotics has a 52 week low of $45.20 and a 52 week high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02.

Insider Buying and Selling

In other news, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares in the company, valued at $5,096,605.36. This represents a 34.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Reza Zadno sold 26,420 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $92.57, for a total transaction of $2,445,699.40. Following the transaction, the chief executive officer now owns 205,605 shares of the company’s stock, valued at approximately $19,032,854.85. This represents a 11.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,355 shares of company stock valued at $10,327,788. Company insiders own 17.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on PRCT. Jefferies Financial Group began coverage on shares of PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a “hold” rating and a $95.00 target price for the company. Morgan Stanley began coverage on shares of PROCEPT BioRobotics in a research report on Monday, December 2nd. They issued an “overweight” rating and a $105.00 price objective for the company. Wells Fargo & Company restated an “overweight” rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Finally, Truist Financial restated a “buy” rating and issued a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).